Abstract
Background: Alzheimer’s disease (AD) is a neurodegenerative disorder histopathologically characterized by the accumulation of amyloid β (Aβ) peptides and inflammation associated with activated microglia. These features are well investigated in the central nervous system using AD-model mice; however, peripheral inflammation in these mice has not been investigated well.
Objective: We evaluated the inflammatory responses, especially myeloid dendritic cells (mDCs), in peripheral lymphoid tissues in AD-model mice to determine their association with Aβ deposition.
Methods: We collected lymphocytes from mesenteric lymphoid nodes (MLNs) and Peyer’s patches (PPs) of 5×FAD transgenic mice used as an AD model. Lymphocytes were analyzed using a flow cytometer to characterize mDCs and T cells. Collected lymphocytes were treated with Aβ1-42 ex vivo to evaluate the inflammatory response.
Results: We observed elevated levels of inflammatory cytokines and chemokines including interleukin (IL)-12 and macrophage inflammatory protein-1α in mDCs from MLNs and PPs and reduced levels of programmed death-ligand-1, an immunosuppressive co-stimulatory molecule, on the surface of mDCs from 5×FAD mice. Additionally, we found increases in interferon (IFN)-γ-producing CD4- or CD8- positive T cells in MLNs were increased in 5×FAD mice. Moreover, ex vivo treatment with Aβ peptides increased the production of IL-12 and IFN-γ by lymphocytes from 5×FAD mice.
Conclusion: The present study showed that pro-inflammatory mDC and T cells were induced in MLNs and PPs of 5×FAD mice.
Keywords: Alzheimer's disease, amyloid β, mesenteric lymphoid node, myeloid dendritic cells, Peyer’s patch, T cells.
[http://dx.doi.org/10.3233/JAD-2010-1221] [PMID: 20061647]
[http://dx.doi.org/10.1146/annurev-neuro-061010-113613] [PMID: 21456963]
[http://dx.doi.org/10.1016/j.brainresbull.2016.08.009] [PMID: 27545490]
[http://dx.doi.org/10.1083/jcb.201709069] [PMID: 29196460]
[http://dx.doi.org/10.3389/fnagi.2018.00140] [PMID: 29867449]
[http://dx.doi.org/10.1172/JCI90606] [PMID: 28862638]
[http://dx.doi.org/10.2174/187152710791012071] [PMID: 20205644]
[http://dx.doi.org/10.1073/pnas.1604263113] [PMID: 27601660]
[http://dx.doi.org/10.1006/nbdi.2002.0556] [PMID: 12505423]
[http://dx.doi.org/10.1212/WNL.0000000000000663] [PMID: 24991028]
[http://dx.doi.org/10.1093/brain/awy265] [PMID: 30403785]
[http://dx.doi.org/10.3233/JAD-142259] [PMID: 25408221]
[http://dx.doi.org/10.3233/JAD-120511] [PMID: 23531500]
[http://dx.doi.org/10.1007/s11481-011-9327-y]
[http://dx.doi.org/10.1093/brain/awv408] [PMID: 26912648]
[http://dx.doi.org/10.3233/JAD-161141] [PMID: 28372330]
[http://dx.doi.org/10.3389/fpsyt.2018.00223] [PMID: 29896129]
[http://dx.doi.org/10.1523/JNEUROSCI.1202-06.2006] [PMID: 17021169]
[http://dx.doi.org/10.1038/s41598-017-14446-1] [PMID: 29066789]
[http://dx.doi.org/10.1371/journal.pone.0032588] [PMID: 22505996]
[http://dx.doi.org/10.1371/journal.pone.0118512] [PMID: 25760987]
[http://dx.doi.org/10.1074/jbc.M116.763813] [PMID: 28087694]
[http://dx.doi.org/10.1016/j.neurobiolaging.2007.06.007] [PMID: 17658667]
[http://dx.doi.org/10.3389/fimmu.2015.00632] [PMID: 26734003]
[http://dx.doi.org/10.1093/brain/aww270] [PMID: 27818384]
[http://dx.doi.org/10.18632/oncotarget.12469] [PMID: ]27713140]
[http://dx.doi.org/10.1084/jem.192.3.405] [PMID: 10934228]
[http://dx.doi.org/10.4049/jimmunol.164.9.4507]
[http://dx.doi.org/10.1186/2045-3701-1-20] [PMID: 21711933]
[http://dx.doi.org/10.1371/journal.pone.0044266] [PMID: 22962607]
[http://dx.doi.org/10.1016/S1074-7613(94)80021-9] [PMID: 7534620]
[http://dx.doi.org/10.1016/j.cellimm.2014.05.006] [PMID: 24908630]
[http://dx.doi.org/10.1016/S1074-7613(02)00362-X] [PMID: 12196291]